The combination of targeting of GOT1 and IACS-010759 reduced its concentration required to effectively inhibit CRC growth, suggesting that this combination may mitigate the dose-limiting toxicities of OXPHOS inhibitors. Here, GOT1 is linked to colorectal carcinoma.